315 results on '"Grynberg, Michaël"'
Search Results
2. Effect of breast cancer prognostic factors on ovarian reserve and response in fertility preservation
3. Fertility outcomes several years after urgent fertility preservation for patients with breast cancer
4. Ovarian reserve in patients with FMR1 gene premutation and the role of fertility preservation
5. Impact of oxygen tension during in vitro maturation: a sibling-oocyte prospective double-blinded study
6. Prospective multicenter observational real-world study to assess the use, efficacy and safety profile of follitropin delta during IVF/ICSI procedures (DELTA Study)
7. Oocyte vitrification for fertility preservation following COS does not delay the initiation of neoadjuvant chemotherapy for breast cancer compared to IVM
8. Medical Treatments for Ovarian Protection
9. Fertility Preservation in Turner Syndrome and Other Gonadal Dysgenesis
10. Searching for the optimal number of oocytes to reach a live birth after in vitro fertilization: a systematic review with meta-analysis
11. Disease-free survival does not differ according to fertility preservation technique for young women with breast cancer
12. A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose
13. Fertility preservation in teenage girls, for non- oncological indications
14. What should be done in terms of fertility preservation for patients with cancer? The French 2021 guidelines
15. Fertility of tomorrow: Are there any restrictions left?
16. Position statement on the diagnosis and management of premature/primary ovarian insufficiency (except Turner Syndrome)
17. Fertility preservation before cancer treatment: the dilemma of saying ‘no’ as the price of glory
18. Fertility Considerations and the Pediatric Cancer Patient
19. Perspectives on the development and future of oocyte IVM in clinical practice
20. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation
21. Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkers
22. Telomere aberrations, including telomere loss, doublets, and extreme shortening, are increased in patients with infertility
23. National survey on the opinions of French specialists in assisted reproductive technologies about social issues impacting the future revision of the French Bioethics laws
24. Use of the EFI score in endometriosis-associated infertility: A cost-effectiveness study
25. First follow-up of art pregnancies in the context of the COVID-19 outbreak
26. In vitro maturation of oocytes for preserving fertility in autoimmune premature ovarian insufficiency
27. Priming Before In Vitro Maturation Cycles in Cancer Patients Undergoing Urgent Fertility Preservation: a Randomized Controlled Study
28. Oncofertilité et cancer du sein
29. Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients
30. Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials
31. Anti Müllerian Hormone: More than a biomarker of female reproductive function
32. Dysfunction of Human Estrogen Signaling as a Novel Molecular Signature of Polycystic Ovary Syndrome
33. Embryo transfer strategy and therapeutic options in infertile patients with thin endometrium: a systematic review
34. Using serum anti-Müllerian hormone levels to predict the chance of live birth after spontaneous or assisted conception: a systematic review and meta-analysis
35. Should we consider day-2 and day-3 embryo morphology before day-5 transfer when blastocysts reach a similar good quality?
36. Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible
37. Fertility Preservation in Endocrine Disorders during Transition for Girls
38. Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin’s lymphoma when compared with breast cancer candidates for fertility preservation
39. Is it acceptable to destroy or include human embryos before day 5 in research programmes?
40. RISK OF SERIOUS ADVERSE EVENT AFTER FERTILITY PRESERVATION PROCEDURES: A COMPARISON OF CANCER AND NON-CANCER PATIENTS
41. DOES A HIGH NUMBER OF MATURE OOCYTES ON THE SAME VITRIFICATION STRAW REDUCE THE POST WARMUP BIOLOGICAL OUTCOMES?
42. FERTILITY OUTCOMES SEVERAL YEARS AFTER FERTILITY PRESERVATION FOR ENDOMETRIOSIS
43. Fertility Preservation in Women
44. In vitro maturation of oocytes: uncommon indications
45. Dysregulation of the Anti-Müllerian Hormone System by Steroids in Women With Polycystic Ovary Syndrome
46. Students’ views on the impact of two pedagogical tools for the teaching of breast and pelvic examination techniques (video-clip and training model): a comparative study
47. Treatment of Twenty-Two Patients with Complete Uterine and Vaginal Septum
48. Influence of breast cancer prognostic factors on oocyte in vitro maturation outcomes performed for urgent fertility preservation
49. Things Are Worse than We Think: Trademark Defenses in a "Formalist" Age
50. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.